Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount [Reuters]

Coherus BioSciences, Inc. (CHRS) 
Last coherus biosciences, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.coherus.com
Company Research Source: Reuters
Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount | Reuters 1 Min Read (Reuters) - Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc’s infection-fighting treatment, Neulasta, at a 33 percent discount. The list price of $4,175 per unit set by Coherus is the same as Mylan NV’s biosimilar Fulphila that was approved earlier this year. Coherus intends to launch the biosimilar, Udenyca, on Jan. 3, it said on a conference call. Udenyca, the second approved copycat version to Neulasta, received approval from the U.S. Food and Drug Administration last week. Neulasta, used to fight infections in cancer patients, has a list price of $6,231 per unit, and brought Amgen revenue of $4.53 billion in 2017. Coherus on Thursday also reported a bigger-than expected quarterly loss of 87 cents per share. Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Maju Samuel All quotes delayed a minimum of 15 minutes. See here for a complete list of exch Show less Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
CHRS alerts

from News Quantified
Opt-in for
CHRS alerts

from News Quantified